Next generation cancer immunotherapeutics

Lokon Pharma develops immunostimulatory gene therapy for cancer utilizing oncolytic viruses as gene delivery vehicles into the cancer lesions. The gene therapy will change the tumor microenvironment so it will stimulate the body's own immune system to seek and destroy cancer cells. At the same time, the viral gene vehicle is designed to replicate in cancer cells only. Replication will continue until the cancer cell dies in a process called oncolysis.


LOAd703 is our first gene therapy being tested in clinical trials and it is currently being evaluated in pancreatic cancer, ovarian cancer, colorectal cancer, biliary cancer and melanoma. 

Developing cutting-edge 

cancer immunotherapy